In the present study, molecular docking method is used for the screening of molecules from plant sources. Based on the literature, ERα, PR, EGFR and, mTOR were selected as targets for the screening of phytochemicals, as these are involved in cancer development and the list of top 20 potential lead molecules against their respective target breast cancer proteins along with binding energy (MMGBSA) and binding affinity (XP G Score) has been presented in Table . Our observation is further strengthened by available literature, which revealed the antichemotherapeutic potential of these phytochemicals against breast cancer. Delphinidin, Parthenosin, and Kaempferol was found effective in in-vitro as well as in-vivo model for breast cancer treatment . Morphine and Rutin targeting mTOR was found effective anti-breast cancer drug in in-vivo studies . Nodifloretin, Jaceosidin, Nepetin, and Vitexin targeting PR were not studied yet for their efficacy in breast cancer treatment however few In vitro & In vivo studies have already been done for other human cancers which includes colon, bladder and cervical cancer . Although, our study shows that IsoSkimmiwallin exhibit higher binding towards NUDT5, but its therapeutic efficacy in breast cancer treatment is not evaluated so far. However, in vitro as well as in vivo therapeutic efficacy of other phytochemicals Isoflavone, Delphinidin, Casuarin and Gossypetin for various types of cancers has already been well documented . The anticancer properties reported so far in literature for proposed lead phytochemical molecules for the treatment of various types of cancer have been presented in table 2. Our study indicated that Delphinidin interacted with more that one breast cancer risk factor which include EGFR and NUDT5 and therefore its evaluation of its therapeutic efficacy in breast cancer model would be beneficial. Further, IsoSkimmiwallin, vitexin Nodifloretin, Jaceosidin and Nepetin shows higher binding interaction with hotspot proteins responsible for breast cancer, but they are not evaluated for breast cancer treatment yet and therefore needs further study.